High-dose chemo and stem cell transplant for T-cell lymphoma patients in remission
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether high-dose chemotherapy followed by a stem cell transplant using your own cells can help people with certain types of peripheral T-cell lymphoma live longer. You would qualify if you have already finished your first round of chemotherapy and are in complete remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with one of these types of T-cell lymphoma: anaplastic large cell lymphoma (ALK-negative), angioimmunoblastic T-cell lymphoma, nodal PTCL with TFH phenotype, or peripheral T-cell lymphoma not otherwise specified.
- You finished your first chemotherapy treatment (which included an anthracycline drug) and are in complete remission, confirmed by a PET-CT scan with a Deauville score of 1-3.
- You are healthy enough to undergo high-dose chemotherapy and a stem cell transplant, as determined by your transplant center.
- Your blood counts and liver function are within certain limits (tested within 2 weeks before joining).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether doing an autologous stem cell transplant (using your own stem cells) after a complete response helps people with certain T-cell lymphomas stay in remission longer. It may be an option if your lymphoma has shrunk completely and you fit the safety and testing requirements.
This trial tests if giving a tailored treatment after first complete remission can improve outcomes for certain types of peripheral T-cell lymphoma. It is for people who have finished initial standard chemotherapy with a complete response.
This study compares two types of stem cell transplants (from a donor or your own cells) for people with certain T-cell lymphomas who had only a partial response to first chemotherapy. It aims to see which approach may work better.
This trial tests giving a donor stem cell transplant (called allo-PBSCT) as the first treatment after chemotherapy for people with high-risk peripheral T-cell lymphoma. It may help prevent the lymphoma from coming back.
This trial compares two types of stem cell transplants (one using donor cells, the other using your own cells) to see which works better for adults with a certain stage of T-cell lymphoma who have already responded well to initial chemotherapy.
This trial tests a combination of two chemotherapy drugs (pralatrexate and bendamustine) plus total-body radiation before a donor stem cell transplant for people with T-cell lymphoma that has come back or hasn't responded to treatment. The goal is to see if this approach can help destroy the lymphoma and allow the donor cells to take hold safely.
Hear when a new Anaplastic Large Cell Lymphoma, ALK-negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.